Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis

A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers

(2017) D. Shin et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis

(2017) Michael E. Weinblatt et al.   Arthritis & Rheumatology

AB0308 A Phase I Pharmacokinetic Study Comparing Pre-Filled Pen and Pre-Filled Syringe of SB5, An Adalimumab Biosimilar in Healthy Subjects: Table 1.

(2016) D. Shin et al.   ANNALS OF THE RHEUMATIC DISEASES

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Biosimilars: A cure to the U.S. health care cost conundrum?

(2014) Bradford R. Hirsch et al.   BLOOD REVIEWS

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis — Results of the BetaPlus observational cohort study

(2011) Carlo Pozzilli et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

State-of-the-art: rheumatoid arthritis

(2010) I. B. McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen

(2010) Joaquín Borrás-Blasco et al.   EXPERT OPINION ON BIOLOGICAL THERAPY